Aclarion, Inc.【ACON】
時価総額
$187.5万
PER
MRSを用いた椎間板性腰痛の非侵襲診断技術の新興企業。NOCISCANなどの定量的バイオマーカー解析を用いる診断プラットフォームを展開。2022年4月のIPOと2025年1月・3月の逆株式分割(1:335、1:27)実施、従業員6名体制。米国中心に展開、2025年Q1にPHILIPSとの初顧客連携開始。
| 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Revenue | 60,444 | 75,404 | 45,724 |
| Cost of revenue | 65,298 | 75,728 | 84,658 |
| Gross profit (loss) | -4,854 | -324 | -38,934 |
| Sales and marketing | 537,069 | 757,004 | 976,554 |
| Research and development | 1 | 873,336 | 888,766 |
| General and administrative | 4 | 3 | 4 |
| Total operating expenses | 6 | 5 | 5 |
| Income (loss) from operations | -6,098,516 | -4,875,981 | -5,513,047 |
| Interest expense | - | - | 535,470 |
| Gain (Loss) on settlement of debt | - | - | 6,058 |
| Gain (Loss) on exchange of debt | - | - | 1 |
| Changes in fair value of warrant and derivative liabilities | - | 646,319 | 335,033 |
| Penalties and settlements | - | - | 212,453 |
| Other, net | 520 | -562 | 269 |
| Total other income (expense) | -1,507,026 | -35,393 | -1,479,880 |
| Income (loss) before income taxes | - | -4,911,374 | -6,992,927 |
| Net income (loss) | -7,605,542 | -4,911,374 | -6,992,927 |
| Dividends accrued for preferred stockholders | 415,523 | - | 59,675 |
| Net income (loss) allocable to common stockholders | -8,021,064 | -4,911,374 | -7,052,602 |
| Net (loss) per share allocable to common shareholders, basic | - | - | -7,480 |
| Net (loss) per share allocable to common shareholders, diluted | - | - | -7,480 |